REGENERON ANNOUNCES POSITIVE PHASE I TRIAL RESULTS FOR VEGF TRAP TO TREAT AGE-RELATED MACULAR DEGENERATION

Regeneron Pharmaceuticals May 1 announced positive preliminary results from its Phase I trial of the Vascular Endothelial Growth Factor (VEGF) trap to treat patients with the neovascular form of age-related macular degeneration (AMD), or wet AMD.

The device met its primary endpoints of safety and tolerability at all dose levels, and also showed positive preliminary efficacy results, the company said. The company has announced the start of a Phase II trial in wet AMD following the positivePhase I results. Phase I trial data were presented at the 2006 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and can be viewed at www.regeneron.com (http://www.regeneron.com).